X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/06/14/2898850/0/en/Shattuck-Labs-Announces-Updated-Positive-Interim-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-in-Combination-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myel.html
https://www.globenewswire.com/news-release/2024/06/06/2894572/0/en/Shattuck-Labs-to-Host-Investor-Call-and-Webcast-on-Additional-Interim-Data-Presented-at-the-European-Hematology-Association-EHA-2024-Congress-from-the-Phase-1B-Dose-Expansion-Clini.html
https://www.prnewswire.com/news-releases/live-from-asco-2024--updated-data-of-bcl-2-inhibitor-lisaftoclax-combined-with-azacitidine-in-patients-with-aml-demonstrate-promising-efficacy-and-manageable-safety-302162771.html
https://www.globenewswire.com/news-release/2024/05/28/2888943/0/en/HiberCell-Announces-First-Patient-Dosed-in-Phase-1b-Clinical-Trial-Evaluating-HC-7366-in-Combination-with-Venetoclax-and-Azacitidine-for-the-Treatment-of-Acute-Myeloid-Leukemia-AML.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212580
https://www.globenewswire.com/news-release/2024/05/14/2881907/0/en/Shattuck-Labs-to-Present-Additional-Data-from-the-Phase-1B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-AZA-in-Frontline-Higher-Risk-Myelodysplastic-Syndromes-HR-MDS.html
https://www.globenewswire.com/news-release/2024/03/22/2851134/0/en/Salarius-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com//news-release/2024/01/03/2803302/0/en/Investigator-initiated-Phase-1-2-Clinical-Trial-Using-Salarius-Pharmaceuticals-Seclidemstat-in-Combination-with-Azacitidine-to-Treat-Hematologic-Cancers-Resumes-Patient-Enrollment.html
https://www.prnewswire.com/news-releases/akeso-published-results-from-cd47-antibody-ligufalimab-in-combination-with-azacitidine-for-newly-diagnosed-higher-risk-myelodysplastic-syndrome-and-treatment-naive-acute-myeloid-leukemia-at-ash-2023-302016538.html
https://www.globenewswire.com//news-release/2023/12/13/2795366/0/en/Shattuck-Labs-Announces-Positive-Initial-Topline-Data-from-Ongoing-Phase-1-A-B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-in-Frontline-Higher-Risk-Myelodysplastic-.html
https://www.prnewswire.com/news-releases/akeso-announced-fda-clearance-of-ind-for-cd47-monoclonal-antibody-ak117-in--combination-with-azacitidine-in-myelodysplastic-syndromes-301941140.html
https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds
https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215066
https://www.globenewswire.com//news-release/2022/12/12/2572191/0/en/ORYZON-Presents-Final-Data-From-Phase-IIa-ALICE-Trial-in-Unfit-AML-Patients-with-First-line-Treatment-of-Iadademstat-and-Azacitidine-in-Oral-Presentation-at-ASH-2022.html
https://www.globenewswire.com//news-release/2022/12/12/2572030/0/en/ALX-Oncology-Announces-Initial-Data-from-ASPEN-05-Study-of-Evorpacept-in-Combination-with-Azacitidine-and-Venetoclax-Demonstrating-Tolerability-and-Preliminary-Activity-in-Patients.html
https://www.accesswire.com/731275/100-Clinical-Benefit-Rate-Achieved-in-Phase-1b-Trial-Evaluating-APVO436-in-Combination-with-Venetoclax-and-Azacitidine-for-Venetoclax-Treatment-Nave-Patients-with-Acute-Myeloid-Leukemia-AML
https://www.prnewswire.com/news-releases/innovent-presents-phase-1b-clinical-data-of-ibi188-anti-cd47-monoclonal-antibody-at-the-2022-american-society-of-hematology-annual-meeting-301699052.html
https://apnews.com/article/health-cancer-clinical-trials-8a62525c9b47e96447f4f108dfd42791
https://www.prnewswire.com/news-releases/i-mab-announces-approval-from-china-cde-to-initiate-phase-3-registrational-study-of-lemzoparlimab-in-combination-with-azacitidine-in-higher-risk-myelodysplastic-syndrome-301622810.html
https://www.prnewswire.com/news-releases/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-in-patients-with-higher-risk-myelodysplastic-syndrome-at-esmo-2022-301621532.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-24-2022-1661335123.pdf
https://endpts.com/abbvie-calls-off-phi-trial-for-i-mabs-cd47-days-after-zai-lab-shelves-its-own-program/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-17-2022-1660735823.pdf
https://www.globenewswire.com/news-release/2022/06/10/2460446/0/en/ORYZON-at-EHA-2022-Iadademstat-42-month-ALICE-Data-Demonstrate-Robust-Efficacy-in-Combination-with-Azacitidine-in-AML.html
https://endpts.com/servier-expands-tibsovo-label-with-first-combination-ok-in-a-rare-form-of-aml/
https://www.asiaone.com/business/servier-announces-fda-approval-tibsovo-ivosidenib-tablets-combination-azacitidine-patients
https://endpts.com/bristol-myers-dusts-off-an-old-celgene-chemotherapy-for-use-in-children-with-a-rare-blood-cancer/
https://www.prnewswire.com/news-releases/phase-3-agile-data-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-published-in-the-new-england-journal-of-medicine-301529694.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-02-2022-1646291076.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211549
https://endpts.com/in-a-setback-fda-orders-gilead-to-hit-the-brakes-on-their-late-stage-5b-cancer-play/
https://www.fiercepharma.com/pharma/astellas-aml-drug-xospata-failed-its-trial-but-further-analysis-shows-it-benefited-some
https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-announces-initial-data-aspen-02-ongoing-phase-1-2
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-azacitidine-1637387689.pdf
https://endpts.com/fda-orders-clinical-hold-on-apreas-p53-reactivator-as-struggling-biotech-pledges-to-address-safety-concerns/
https://www.globenewswire.com/news-release/2021/07/06/2258077/33016/en/Trillium-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1b-2-Study-of-TTI-622-in-Combination-With-Azacitidine-and-Venetoclax-in-TP53-Wild-Type-Acute-Myeloid-Leukemia.html
Market Place
Share 
